• news.cision.com/
  • Redsense/
  • Redsense receives positive Final Notice regarding novel optical monitoring – will obtain patent approval in Sweden

Redsense receives positive Final Notice regarding novel optical monitoring – will obtain patent approval in Sweden

Report this content

Redsense Medical AB announces the receipt of a Final Notice with regard to the patent application for the second invention related to the Company’s smart wound care technology for optical measuring of blood and exudate. The Final Notice expresses PRV’s intent to approve the application under the condition that certain modifications are made no later than 4 May 2020.

On 2 September 2019, Redsense Medical submitted a patent application for a ‘method and device for monitoring a measurement object’.  The application relates to a novel stand-alone invention that supports the existing wound care technology developed by the Company. This second invention derives from the company’s work on its previously granted Swedish patent for smart bandages – ‘A Device for measuring a property of a measurement object by luminescence’ – which also received a favourable international patent search report and written opinion in October 2019.

In beginning of March 2020, Redsense received a Final Notice from PRV (The Swedish Patent and Registration Office) regarding the second application; according to the notice, PRV intends to grant the patent application under the condition that certain changes are made no later than 4 May 2020. The changes comprise minor corrections to the drawing and description. The Company will submit the necessary changes and further intends to submit an international PCT patent application for the technology once the Swedish patent is approved.

The Patent and Registration Office finds no other obstacles to patentability provided that these minor rectifications are provided on time. This positive statement from PRV marks the next step in our patent protection process; we have aimed from the start to create a strong protection for our potentially revolutionary smart wound care technology on all relevant markets, and we are making steady progress towards that goal.” says Redsense Medical’s CEO Patrik Byhmer.

Redsense’s smart wound care technology employs thin sensor layers to measure several physiological and biological parameters such as blood and exudate optically. The sensor layers can be used separately or integrated directly into smart bandages or adhesive plasters, enabling cost and resource effective individual wound care.

For more information, please contact:

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30




Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.